MX2016014346A - Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada. - Google Patents

Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada.

Info

Publication number
MX2016014346A
MX2016014346A MX2016014346A MX2016014346A MX2016014346A MX 2016014346 A MX2016014346 A MX 2016014346A MX 2016014346 A MX2016014346 A MX 2016014346A MX 2016014346 A MX2016014346 A MX 2016014346A MX 2016014346 A MX2016014346 A MX 2016014346A
Authority
MX
Mexico
Prior art keywords
mercaptopurine
crohn
disease
delayed
release
Prior art date
Application number
MX2016014346A
Other languages
English (en)
Inventor
KOLATCH Brenda
Hotovely-Salomon Anna
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2016014346A publication Critical patent/MX2016014346A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos para tratar pacientes que padecen de enfermedad de Crohn o colitis ulcerosa quienes no experimentan una respuesta clínica la administración previa de tiopurina, o padecen efectos colaterales a partir de la administración previa de tiopurina, al administrar una composición farmacéutica de liberación prolongada que comprende 6-mercaptopurina. También se describen métodos para tratar pacientes que padecen de enfermedad de Crohn o colitis ulcerosa a quienes se les ha administrado un esteroide, ácido 5-aminosalicílico, o un antibiótico al administrar adyuvantemente una composición farmacéutica de liberación prolongada que comprende 6-mercaptopurina.
MX2016014346A 2014-05-02 2015-04-30 Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada. MX2016014346A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988068P 2014-05-02 2014-05-02
US201462093210P 2014-12-17 2014-12-17
PCT/US2015/028590 WO2015168448A1 (en) 2014-05-02 2015-04-30 Treatment of crohn's disease with delayed-release 6-mercaptopurine

Publications (1)

Publication Number Publication Date
MX2016014346A true MX2016014346A (es) 2017-04-27

Family

ID=54354388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014346A MX2016014346A (es) 2014-05-02 2015-04-30 Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada.

Country Status (8)

Country Link
US (2) US20150313904A1 (es)
EP (1) EP3137063A4 (es)
JP (1) JP2017514837A (es)
CA (1) CA2947291A1 (es)
IL (1) IL248592A0 (es)
MX (1) MX2016014346A (es)
TW (1) TW201622727A (es)
WO (1) WO2015168448A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
CA3121162A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
PH12022550978A1 (en) 2019-10-24 2023-10-09 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263482A1 (en) * 2008-04-18 2009-10-22 Vered Rosenberger Treatment of inflammatory bowel disease with 6-mercaptopurine

Also Published As

Publication number Publication date
US20180015094A1 (en) 2018-01-18
EP3137063A4 (en) 2017-12-13
IL248592A0 (en) 2016-12-29
WO2015168448A1 (en) 2015-11-05
EP3137063A1 (en) 2017-03-08
JP2017514837A (ja) 2017-06-08
US20150313904A1 (en) 2015-11-05
CA2947291A1 (en) 2015-11-05
TW201622727A (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
MX2016014346A (es) Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada.
JP2015057451A5 (es)
IL254746A0 (en) A system and method for controlling the administration of a drug to a patient
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PT3277295T (pt) Composição para o tratamento de um estado metabólico patogénico da flora intestinal e de doenças derivadas
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
WO2016054480A3 (en) Venous access catheters and methods for portal venous system catheterization
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MY193963A (en) Composition for treating joint diseases and kit containing same
GB2558494B (en) Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
IN2014DN09240A (es)
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
AR100262A1 (es) Tratamiento de la enfermedad de crohn con 6-mercaptopurina de liberación demorada
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
WO2016115442A3 (en) Therapeutic protein formulations